Skip to main content
Top
Published in: BMC Infectious Diseases 1/2007

Open Access 01-12-2007 | Research article

The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study

Authors: Paulo N Rocha, Ana Paula Rehem, Juliana F Santana, Neviton Castro, Andre L Muniz, Katia Salgado, Heonir Rocha, Edgar M Carvalho

Published in: BMC Infectious Diseases | Issue 1/2007

Login to get access

Abstract

Background

HTLV-I infected patients often complain of urinary symptomatology. Epidemiological studies have suggested that these individuals have a higher prevalence and incidence of urinary tract infection (UTI) than seronegative controls. However, the diagnosis of UTI in these studies relied only on patient information and did not require confirmation by urine culture. The purpose of this study was to investigate the role of urinary tract infection (UTI) as the cause of urinary symptoms in HTLV-I infected patients.

Methods

In this cross sectional study we interviewed, and cultured urine from, 157 HTLV-I seropositive individuals followed regularly at a specialized clinic. All patients were evaluated by a neurologist and classified according to the Expanded Disability Status Scale (EDSS). Urodynamic studies were performed at the discretion of the treating physician.

Results

Sixty-four patients complained of at least one active urinary symptom but UTI was confirmed by a positive urine culture in only 12 of these patients (19%); the majority of symptomatic patients (81%) had negative urine cultures. To investigate the mechanism behind the urinary complaints in symptomatic individuals with negative urine cultures, we reviewed the results of urodynamic studies performed in 21 of these patients. Most of them (90.5%) had abnormal findings. The predominant abnormalities were detrusor sphincter hyperreflexia and dyssynergia, findings consistent with HTLV-I-induced neurogenic bladder. On a multivariate logistic regression, an abnormal EDSS score was the strongest predictor of urinary symptomatology (OR 9.87, 95% CI 3.465 to 28.116, P < 0.0001).

Conclusion

Urinary symptomatology suggestive of UTI is highly prevalent among HTLV-I seropositive individuals but true UTI is responsible for the minority of cases. We posit that the main cause of urinary symptoms in this population is neurogenic bladder. Our data imply that HLTV-I infected patients with urinary symptomatology should not be empirically treated for UTI but rather undergo urine culture; if a UTI is excluded, further investigation with urodynamic studies should be considered.
Appendix
Available only for authorised users
Literature
1.
go back to reference Murphy EL, Glynn SA, Fridey J, Sacher RA, Smith JW, Wright DJ, Newman B, Gibble JW, Ameti DI, Nass CC, Schreiber GB, Nemo GJ: Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis. 1997, 176: 1468-1475.CrossRefPubMed Murphy EL, Glynn SA, Fridey J, Sacher RA, Smith JW, Wright DJ, Newman B, Gibble JW, Ameti DI, Nass CC, Schreiber GB, Nemo GJ: Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis. 1997, 176: 1468-1475.CrossRefPubMed
2.
go back to reference Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, Ownby HE, Wright DJ, Nemo GJ: Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med. 1999, 159: 1485-1491. 10.1001/archinte.159.13.1485.CrossRefPubMed Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, Ownby HE, Wright DJ, Nemo GJ: Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med. 1999, 159: 1485-1491. 10.1001/archinte.159.13.1485.CrossRefPubMed
3.
go back to reference Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, Newman B, Ownby HE, Garratty G, Hutching ST, Schreiber GB: Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. 2004, 10: 109-116.CrossRefPubMedPubMedCentral Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, Newman B, Ownby HE, Garratty G, Hutching ST, Schreiber GB: Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. 2004, 10: 109-116.CrossRefPubMedPubMedCentral
4.
go back to reference Dourado I, Alcantara LC, Barreto ML, da Gloria TM, Galvao-Castro B: HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003, 34: 527-531. 10.1097/00126334-200312150-00013.CrossRefPubMed Dourado I, Alcantara LC, Barreto ML, da Gloria TM, Galvao-Castro B: HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003, 34: 527-531. 10.1097/00126334-200312150-00013.CrossRefPubMed
5.
go back to reference Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-1452.CrossRefPubMed Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-1452.CrossRefPubMed
6.
go back to reference De Castro-Costa CM, Araujo AQ, Barreto MM, Takayanagui OM, Sohler MP, da Silva EL, de Paula SM, Ishak R, Ribas JG, Rovirosa LC, Carton H, Gotuzzo E, Hall WW, Montano S, Murphy EL, Oger J, Remondegui C, Taylor GP: Proposal for Diagnostic Criteria of Tropical Spastic Paraparesis/HTLV-I-Associated Myelopathy (TSP/HAM). AIDS Res Hum Retroviruses. 2006, 22: 931-935. 10.1089/aid.2006.22.931.CrossRefPubMed De Castro-Costa CM, Araujo AQ, Barreto MM, Takayanagui OM, Sohler MP, da Silva EL, de Paula SM, Ishak R, Ribas JG, Rovirosa LC, Carton H, Gotuzzo E, Hall WW, Montano S, Murphy EL, Oger J, Remondegui C, Taylor GP: Proposal for Diagnostic Criteria of Tropical Spastic Paraparesis/HTLV-I-Associated Myelopathy (TSP/HAM). AIDS Res Hum Retroviruses. 2006, 22: 931-935. 10.1089/aid.2006.22.931.CrossRefPubMed
7.
go back to reference National Committee for Clinical Laboratory Standards: Supplemental table M100-S4 to: Performance standards for antimicrobial disk susceptibility tests, 4th ed. Document M2-A4, 1990. 1992, Villanova, Pa National Committee for Clinical Laboratory Standards: Supplemental table M100-S4 to: Performance standards for antimicrobial disk susceptibility tests, 4th ed. Document M2-A4, 1990. 1992, Villanova, Pa
8.
go back to reference Platt R: Quantitative definition of bacteriuria. Am J Med. 1983, 75: 44-52. 10.1016/0002-9343(83)90072-4.CrossRefPubMed Platt R: Quantitative definition of bacteriuria. Am J Med. 1983, 75: 44-52. 10.1016/0002-9343(83)90072-4.CrossRefPubMed
9.
go back to reference Heilberg IP, Schor N: [Diagnosis and clinical management of urinary tract infection]. Rev Assoc Med Bras. 2003, 49: 109-116. 10.1590/S0104-42302003000100043.CrossRefPubMed Heilberg IP, Schor N: [Diagnosis and clinical management of urinary tract infection]. Rev Assoc Med Bras. 2003, 49: 109-116. 10.1590/S0104-42302003000100043.CrossRefPubMed
10.
go back to reference Komine S, Yoshida K, Yamashita H, Masaki Z: Voiding dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy (HAM). Paraplegia. 1989, 27: 217-221.CrossRefPubMed Komine S, Yoshida K, Yamashita H, Masaki Z: Voiding dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy (HAM). Paraplegia. 1989, 27: 217-221.CrossRefPubMed
11.
go back to reference Namima T, Sohma F, Imabayashi K, Nishimura Y, Orikasa S: [Two cases of neurogenic bladder due to HTLV-1 associated myelopathy (HAM)]. Nippon Hinyokika Gakkai Zasshi. 1990, 81: 475-478.PubMed Namima T, Sohma F, Imabayashi K, Nishimura Y, Orikasa S: [Two cases of neurogenic bladder due to HTLV-1 associated myelopathy (HAM)]. Nippon Hinyokika Gakkai Zasshi. 1990, 81: 475-478.PubMed
12.
go back to reference Saito M, Kondo A, Kato K, Gotoh M: Bladder dysfunction due to human T-lymphotrophic virus type I associated myelopathy. Br J Urol. 1991, 68: 365-368.CrossRefPubMed Saito M, Kondo A, Kato K, Gotoh M: Bladder dysfunction due to human T-lymphotrophic virus type I associated myelopathy. Br J Urol. 1991, 68: 365-368.CrossRefPubMed
13.
go back to reference Saito M, Kato K, Kondo A, Miyake K: [Neurogenic bladder in HAM (HTLV-I associated myelopathy)]. Hinyokika Kiyo. 1991, 37: 1005-1008.PubMed Saito M, Kato K, Kondo A, Miyake K: [Neurogenic bladder in HAM (HTLV-I associated myelopathy)]. Hinyokika Kiyo. 1991, 37: 1005-1008.PubMed
14.
go back to reference Yamashita H, Kumazawa J: Voiding dysfunction: patients with human T-lymphotropic-virus-type-1-associated myelopathy. Urol Int. 1991, 47 (Suppl 1): 69-71.CrossRefPubMed Yamashita H, Kumazawa J: Voiding dysfunction: patients with human T-lymphotropic-virus-type-1-associated myelopathy. Urol Int. 1991, 47 (Suppl 1): 69-71.CrossRefPubMed
15.
go back to reference Sakiyama H, Nishi K, Kikukawa H, Ueda S: [Urinary disturbance due to HTLV-1 associated myelopathy]. Nippon Hinyokika Gakkai Zasshi. 1992, 83: 2058-2061.PubMed Sakiyama H, Nishi K, Kikukawa H, Ueda S: [Urinary disturbance due to HTLV-1 associated myelopathy]. Nippon Hinyokika Gakkai Zasshi. 1992, 83: 2058-2061.PubMed
16.
go back to reference Walton GW, Kaplan SA: Urinary dysfunction in tropical spastic paraparesis: preliminary urodynamic survey. J Urol. 1993, 150: 930-932.PubMed Walton GW, Kaplan SA: Urinary dysfunction in tropical spastic paraparesis: preliminary urodynamic survey. J Urol. 1993, 150: 930-932.PubMed
17.
go back to reference Imamura A: [Studies on neurogenic bladder due to human T-lymphotropic virus type-I associated myelopathy (HAM)]. Nippon Hinyokika Gakkai Zasshi. 1994, 85: 1106-1115.PubMed Imamura A: [Studies on neurogenic bladder due to human T-lymphotropic virus type-I associated myelopathy (HAM)]. Nippon Hinyokika Gakkai Zasshi. 1994, 85: 1106-1115.PubMed
18.
go back to reference Hattori T, Sakakibara R, Yamanishi T, Yasuda K, Hirayama K: Micturitional disturbance in human T-lymphotropic virus type-1-associated myelopathy. J Spinal Disord. 1994, 7: 255-258.CrossRefPubMed Hattori T, Sakakibara R, Yamanishi T, Yasuda K, Hirayama K: Micturitional disturbance in human T-lymphotropic virus type-1-associated myelopathy. J Spinal Disord. 1994, 7: 255-258.CrossRefPubMed
19.
go back to reference Mehnert-Kay SA: Diagnosis and management of uncomplicated urinary tract infections. Am Fam Physician. 2005, 72: 451-456.PubMed Mehnert-Kay SA: Diagnosis and management of uncomplicated urinary tract infections. Am Fam Physician. 2005, 72: 451-456.PubMed
Metadata
Title
The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study
Authors
Paulo N Rocha
Ana Paula Rehem
Juliana F Santana
Neviton Castro
Andre L Muniz
Katia Salgado
Heonir Rocha
Edgar M Carvalho
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2007
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-7-15

Other articles of this Issue 1/2007

BMC Infectious Diseases 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.